Business Context and Reporting Period
This Form 8-K filing by AcelRx Pharmaceuticals, Inc. (ACRX) reports on events occurring on September 23, 2022. The Company convened a virtual special meeting of stockholders to vote on a proposal to amend its Amended and Restated Certificate of Incorporation. The amendment authorizes the Board of Directors to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for-10 to 1-for-30 within one year of the meeting.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The primary material event was the approval of the Reverse Stock Split Proposal. The voting results were as follows:
- Common Stock: 53,371,108 votes "For", 25,270,193 votes "Against", and 383,282 votes abstaining.
- Series A Preferred Stock: 3,000 shares were present, each carrying 1,000,000 votes, voting in proportion to the Common Stock.
- Total Votes: 2,089,366,469 "For", 989,274,832 "Against", and 383,282 abstaining.
- Outcome: The proposal was approved.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the context of the stock split authorization. The Board retains sole discretion to determine the specific reverse stock split ratio and timing within the authorized one-year window.
Key Facts for Investor Verification
- Stockholders approved the authority for a reverse stock split between 1-for-10 and 1-for-30.
- The specific ratio and effective date of the split have not yet been determined by the Board.
- The filing contains no financial performance data; investors should refer to the Company's most recent 10-Q or 10-K for financial metrics.
- Series A Preferred Stock voted in proportion to the Common Stock on this specific proposal.